Ufuk S. Kumrulu, general manager of Polifarma, and Vildan Kumrulu, member of the board, share how the company has strategized its internal investments in recent years and how it plans to take its portfolio into new markets as well as propel the development of its contract manufacturing arm, AIS Pharma.
Since 2015, Polifarma has undergone a major transformation
Queisser Pharma is a German company focused on the OTC market through food supplements and medical devices. Its general manager for Turkey, Demet Eryilmaz, tells the “special” story of its…
Bıçakcılar is one of Turkey’s largest medical technology companies, selling disposables and focusing on the operating room, any hospital’s most profitable part. Souheil A. ElHakim, the company’s CEO, reflects on…
Genz Biotechnology is a biotech startup working on novel diagnostic testing solutions. Its founder and CEO, Umut Ağyüz, explains the origins of the company, the big opportunities that have arisen…
With an already well-established manufacturing industry for pharmaceuticals, Turkey has been aiming to move with global trends and invest in biologics production, specifically in biosimilars. The share of biotechnological…
Becoming the clinical trials country leader in the region has been set as a primary goal for Turkey’s pharma industry to achieve global competitiveness. The government’s strategy is to increase…
Few Turkish companies are experiencing such a transformational moment as GEN. In 2021 alone, the Ankara-based organization made its public debut on the Istanbul Stock Exchange and signed an exclusive…
See our Cookie Privacy Policy Here